New Enterprise Associates

Cardurion Pharmaceuticals, LLC is a biotechnology company based in Boston, Massachusetts, established in 2017. The company specializes in developing innovative therapeutics aimed at treating heart failure and other cardiovascular diseases. Cardurion is advancing clinical programs that focus on inhibiting PDE9 and CaMKII, utilizing its knowledge of cardiovascular signaling pathways to meet significant patient needs in this area.

NODAR, Inc. is a Boston-based company that specializes in manufacturing advanced sensors for various transportation modes, including cars, trucks, drones, ships, trains, and aircraft. Established in 2018, NODAR focuses on developing cutting-edge camera-based 3D vision systems aimed at enhancing the safety and reliability of autonomous vehicles. Their flagship product, Hammerhead, utilizes off-the-shelf cameras to deliver long-range, ultra-precise depth sensing essential for Level 3 and Level 4 autonomous applications. This technology enables critical functionalities such as collision warning, path planning, and automatic emergency braking, while ensuring cost-effectiveness and high performance. NODAR's innovations target automotive, marine, and railway industries, providing solutions that meet the growing demand for reliable 3D sensing technology in the mainstream automotive market.

Proof of Learn is a talent marketplace focused on educating and placing the next generation of developers. Founded in 2021 and based in Boston, the company operates Metacrafters.io, a multichain learn-to-earn platform that teaches users how to write smart contracts and build on-chain applications. The platform aims to provide equal access to education and job opportunities in the emerging Web3 space, utilizing blockchain technology to create a decentralized model for learning. By empowering learners to gain skills, earn rewards, and secure employment, Proof of Learn addresses the growing demand for qualified talent in the digital economy.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

Akouos, Inc. is a biotechnology company based in Boston, Massachusetts, dedicated to developing gene therapies aimed at restoring, improving, and preserving hearing for individuals affected by various inner ear disorders. Founded in 2016, the company utilizes an innovative platform that includes a proprietary adeno-associated viral vector library and a unique delivery method. Its leading product candidate, AK-OTOF, targets hearing loss resulting from mutations in the OTOF gene. Akouos focuses on genetically-defined patient populations, addressing conditions ranging from single genetic mutations to hearing loss caused by ototoxic drugs and aging. The company has established strategic partnerships with key institutions, including Massachusetts Eye and Ear and Lonza, Inc., to advance its mission of providing precision genetic therapies for sensorineural hearing loss.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Glamsquad, Inc., also known as GLAM Group, is a New York-based company that specializes in providing on-demand beauty services. Founded in 2013, Glamsquad offers a range of services including hair styling, makeup application, and nail care, catering to clients in major cities such as New York City, Los Angeles, Miami, Washington, D.C., Boston, and the San Francisco Bay Area. The company employs a network of trained and vetted beauty professionals who deliver personalized experiences for various occasions, including home appointments, parties, and weddings. Glamsquad leverages technology to facilitate easy booking through its app and website, ensuring clients can select services, schedule appointments, and enjoy the convenience of professional beauty care at home. In addition to services, Glamsquad has introduced its own line of hair and makeup products, designed to complement their offerings and meet client needs.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Influitive Corporation, established in 2010 and headquartered in Toronto, Canada, with offices in Menlo Park, California, and Boston, Massachusetts, specializes in advocate marketing software solutions for B2B software and technology firms. Its flagship product, AdvocateHub, facilitates the creation of advocate communities, enabling customers, partners, and employees to engage in challenges such as referrals, reviews, and reference calls. This software integrates with Salesforce.com for activity tracking and is available via web portal or mobile app. Influitive also offers consulting services, providing coaching and training to help businesses implement and advance their advocate marketing strategies.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.

Motus Therapeutics is a biotechnology company based in Boston, Massachusetts, focused on developing peptide therapeutics to address unmet medical needs in metabolic diseases, particularly gastrointestinal disorders. The company's lead product candidate, relamorelin, is a ghrelin agonist designed to treat diabetic gastroparesis, a complication associated with diabetes, as well as other gastrointestinal functional disorders. Motus Therapeutics aims to provide innovative solutions for patients suffering from these conditions.